Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: A meta-analysis

Nuclear Medicine Communications

Volumn 35, Issue 5, 2014, Pages 484-492

  Gong, Lin ^a,c   Shi, Lu ^c   Sun, Jing ^d   Yuan, Wei Sheng ^c   Chen, Jian Feng ^c   Liu, Peng ^c   Gong, Feng ^b   Dong, Jia Hong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 401 Hospital of PLA   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant therapy; Hepatic resection; Hepatocellular carcinoma; Iodine 131 lipiodol; Recurrence; Survival

Indexed keywords

IODINATED POPPYSEED OIL; IODINE 131; ETHIODIZED OIL; RADIOACTIVE IODINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; META ANALYSIS; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; ETHIODIZED OIL; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; SURVIVAL RATE;

EID: 84897574004     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000081     Document Type: Article

References (36)

1. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27:80-92
2. Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-Arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010; 7:41-49
3. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 (Suppl 3):iii1-iii8
4. Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: Evidence-based outcomes. World J Gastroenterol 2008; 14:685-692
5. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: Risk factors, treatment, and outcomes. Surgery 2007; 141:330-339
6. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, et al. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting Milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg 2007; 204:1-6
7. Nakakuma K, Tashiro S, Hiraoka T, Uemura K. An attempt for increasing effects of hepatic artery ligation for advanced hepatoma. Jap-Deutsch Med Berielite 1979; 24:675-682
8. Iwai K, Konno T, Maeda H. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and x-ray image. Cancer Res 1984; 44:2115-2121
9. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985; 154:15-17
10. Sasaki Y, Imaoka S, Kasugai H. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin and gelatin sponge. Cancer 1987; 60:1194-1203
11. Yoo HS, Suh JH, Lee JT, Kim KW, Kim DI, Kim BS, et al. Nodular hepatocellular carcinoma: Treatment with intraarterial injection of I-131 lipiodol. J Korean Med Sci 1990; 5:75-83
12. Novell R, Hilson A, Hobbs K. Ablation of recurrent primary liver cancer using 131I-lipiodol. Postgrad Med J 1991; 67:393-395
13. Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988; 29:1066-1077
14. Sundram FX. Radionuclide therapy for hepatocellular carcinoma. Biomed Imaging Interv J 2006; 2:e40
15. Raoul JL, Boucher E, Roland Y, Garin E. 131Iodine lipiodol therapy in hepatocellular carcinoma. Q J Nucl Mol Imaging 2005; 53:348-355
16. Garin E, Laffont S, Rolland Y, Olivie D, Lecloirec J, Herry JY, et al. Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003; 24:671-678
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17:1-12
18. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analyses. Available at: Http://www.ohri.ca/ programs/clinical- epidemiology/oxford.htm. [Accessed 23 February 2013].
19. Chung AYF, Ooi LLPJ, Machin D, Tan SB, Goh BKP,Wong JS, et al. Adjuvant hepatic intra-Arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: A prospective randomized trial. World J Surg 2013; 37:1356-1361
20. LauWY, Lai EC, Leung TW, Yu SC. Adjuvant intra-Arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: A prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008; 247:43-48
21. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, et al. Adjuvant intra-Arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomized trial. Lancet 1999; 353:797-801
22. Boucher E, Corbinais S, Rolland Y, Bourguet P, Guyader D, Boudjema K, et al. Adjuvant intra-Arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003; 38:1237-1241
23. Boucher E, Bouguen G, Garin E, Guillygomarch A, Boudjema K, Raoul JL. Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: Progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med 2008; 49:362-366
24. Chua TC, Saxena A, Chu F, Butler SP, Quinn RJ, Glenn D, et al. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: A comparative analysis. Int J Clin Oncol 2011; 16:125-132
25. Tabone M, Vigano' L, Ferrero A, Pellerito R, Carbonatto P, Capussotti L. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 2007; 33:61-66
26. Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K. Resection of hepatocellular carcinoma in noncirrhotic liver: Analysis of risk factors for survival. J Am Coll Surg 2005; 201:663-670
27. Keng GH, Sundram FX, Yu SW, Somanesan S, Premaraj J, Oon CJ, et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-Arterial radio-conjugates. Ann Acad Med Singapore 2002; 31:382-386
28. Ng KM, Niu R, Yan TD, Zhao J, McKay E, Chu FC, et al. Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxford) 2008; 10:388-395
29. Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-Arterial iodine-131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: A phase 2 clinical study. Arch Surg 2000; 135:1298-1300
30. Raoul JL, Messner M, Boucher E, Bretagne JF, Campion JP, Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-Arterial injection of 131I-labelled lipiodol. Br J Surg 2003; 90:1379-1383
31. Chua TC, Chu F, Butler SP, Quinn RJ, Glenn D, Liauw W, et al. Intra-Arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer 2010; 116:4069-4077
32. Madsen MT, Park CH, Thakur ML. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 1988; 29:1038-1044
33. Tabone M, Vigano L, Laudi C, Ferrero A, Pellerito R, Capussotti L. Adjuvant iodine-131-labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: Which is the best treatment schedule? Hepatology 2005; 41:1433 author reply 1433-1434
34. Chen K, Xia Y, Wang H, Xiao F, Xiang G, Shen F. Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: A randomized controlled trial. PLoS One 2013; 8:e57397
35. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003; 238:703-710
36. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: Prognostic and therapeutic implications. Ann Surg 2006; 243:229-235.